Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More powers for European Parliament in time for ATMP (Advanced Therapies Medicinal Products) implementation?

This article was originally published in Clinica

Executive Summary

The European Parliament looks close to gaining the increased powers it desires - and in time to have an influence on implementation of the proposed Advanced Therapies Medicinal Products (ATMP) Regulation, after the text has been adopted. This ATMP Regulation will cover at least some human tissue engineered products, as well as cell and gene therapy products. MEPs have long complained that they have no further say, once their role in the approval of a Directive or Regulation is over, in how the legislation is implemented by way of technical operating rules through "comitology". This is a task delegated to the Commission, acting on the advice of 248 expert committees, often composed of national civil servants. Council then decides whether to approve the rules.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052424

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel